Aldosterone antagonists: Effective add-on therapy for the treatment of resistant hypertension

Expert Review of Cardiovascular Therapy

Volumn 4, Issue 3, 2006, Pages 353-359

  Gaddam, Krishna K ^a   Pratt Ubunama, Monique N ^a   Calhoun, David A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Aldosterone antagonists; Amiloride; Eplerenone; Hyperaldosteronism; Primary aldosteronism; Resistant hypertension; Spironolactone

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DECONGESTIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; GLYCYRRHIZA EXTRACT; HYDROCHLOROTHIAZIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PLACEBO; POTASSIUM; RENIN; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; VERAPAMIL;

ABDOMINAL CRAMP; ADD ON THERAPY; AGING; BIOCHEMISTRY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BREAST TENDERNESS; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; HIGH RISK PATIENT; HUMAN; HYPERALDOSTERONISM; HYPERKALEMIA; HYPERTENSION; OBESITY; PATIENT MONITORING; PLASMA RENIN ACTIVITY; POPULATION RESEARCH; PREVALENCE; PRIMARY HYPERALDOSTERONISM; REVIEW; SEXUAL DYSFUNCTION;

ALDOSTERONE ANTAGONISTS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; SPIRONOLACTONE;

EID: 33744476141     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.4.3.353     Document Type: Review

References (32)

1. Haijar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 290(2), 199-206 (2003).
2. Thaker D, Frech F, Suh D et al. Prevalence of hypertension and ethnic differences in sociodemographic and cardiovascular health characteristics of US hypertensives. Am. J. Hypertens. 18(5), A117 (2005).
3. Hypertension in America: a national reading. Am. J. Manag. Care 11 (Suppl. 13), S383-S385 (2005).
4. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42(6), 1206-1252 (2003).
5. The ALLHAT Officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288(23), 2981-2997 (2002).
6. Black HR, Eliott WJ, Grandits G et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End points (CONVINCE) trial. JAMA 289(16), 2073-2082 (2003).
7. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359(9311), 995-1003 (2002).
8. Logan AG, Perlikowski SM, Mente A et al. High prevalence of unrecognized sleep apnea in drug-resistant hypertension. J. Hypertens. 19(12), 2271-2277 (2001).
9. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin. Exp. Pharmacol. Physiol. 21(4), 315-318 (1994).
10. Gordon RD, Ziesak MD, Tunny TJ, Stowasser M, Klemm SA. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin. Exp. Pharmacol. Physiol. 20, 296-298 (1993).
11. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40(6), 892-896 (2002).
12. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am. J. Kidney Dis. 37(4), 699-705 (2001).
13. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J. Hypertens. 22(11), 2217-2226(2004).
14. Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J Jr. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J. Hum. Hypertens. 17(5), 349-352 (2003).
15. Conn JW. The evolution of primary aldosteronism. Harvey Lect. 62, 257-291 (1968).
16. Bravo El, Tarazi RC, Dustan HP et al. The changing clinical spectrum of primary aldosteronism. Am. J. Med. 74(4), 641-651 (1983).
17. Benchetrit S, Bernheim J, Podjarny E. Normokalemic hyperaldosteronism in patients with resistant hypertension. Isr. Med. Assoc. J. 4(1), 17-20 (2002).
18. Nishizaka. MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am. J. Hypertens. 16(11 Pt 1), 925-930 (2003).
19. Becker HF, Jerrentrup A, Ploch T et al. Effect of nasal continuous positive air-way pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 107(1), 68-73 (2003).
20. Logan AG, Tkacova R, Perlikowski SM et al. Refractory hypertension and sleep apnea: effect of CPAP on blood pressure and baroreflex. Eur. Respir. J. 21(2), 241-247 (2003).
21. Vollmer WM, Sacks FM, Ard J et al. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann. Intern. Med. 135(12), 1019-1028 (2001).
22. Garg JP. Elliott WJ, Folker A et al. Resistant hypertension revisited: a comparision of two university based cohorts. Am. J. Hypertens. 18(5 Pt 1), 619-26 (2005).
23. Ouzan J, Perault C, Lincoff AM, Carre E, Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am J. Hypertens. 15(4 Pt 1), 333-339 (2002).
24. Saha C, Eckert GJ, Ambrosius WT et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 46(3), 481-487 (2005).
25. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J. Hypertens. 15(8), 709-716 (2002).
26. White WB, Duprez D, Hillaire RS et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 41(5), 1021-1026 (2003).
27. Williams GH, Burgess E, Kolloch RE et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am. J. Cardiol. 93(8), 990-6 (2004).
28. Flack JM, Oparil S, Pratt H et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J. Am. J. Cardiol. 41(7), 1148-1155 (2003).
29. Krum H, Nolly H, Workman D et al. Efficacy of eplerenone added to reninangiotensin blockade in hypertensive patients. Hypertension 40(2), 117-23 (2002).
30. Goodfriend TL, Ball DL, Gardner HW. An oxidized derivative of linoleic acid affects aldosterone secretion by adrenal cells in vitro. Prostaglandis Leukot Essent Fatty Acids 67(2-3), 163-167 (2002).
31. Calhoun DA, Nishizaka MK, Zaman MA, Harding SM. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 125(1), 112-117 (2004).
32. Kaplan NM. The current epidemic of primary aldosteronism: causes and consequences. J. Hypertension. 22, 863-869 (2004)